New drug aims to stop kidney transplant rejection

NCT ID NCT07641426

Recruiting now Disease control Sponsor: CASI pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This study tests a new medicine called CID-103 in adults whose kidney transplants are being rejected by their immune system (antibody-mediated rejection). The trial has two parts: first, to find a safe dose, and second, to see if the drug can stop the rejection. About 58 people will take part, receiving the drug by IV for up to 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CID-103 (a monoclonal antibody given by IV infusion)
What this could lead to: If it works, this could point toward a new treatment option for people whose kidney transplants are being rejected and who don't respond to current therapies.
What could go wrong: This is an early Phase 1/2 trial with only 58 participants, so results may not apply to everyone. The drug may cause infections, low blood counts, or infusion reactions, and it may not stop rejection long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACTIVE AND CHRONIC ACTIVE RENAL ALLOGRAFT ANTIBODY MEDIATED REJECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute transplant rejection chronic transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIBODY MEDIATED REJECTION

Contacts and locations

Locations

Beijing Friendship Hospital
ACTIVE_NOT_RECRUITING

Beijing, Beijing Municipality, China
The First Affiliated Hospital of Medical College of Xi'an Jiaotong University
ACTIVE_NOT_RECRUITING

Xi'an, Shaanxi, China
The First Affiliated Hospital of Sun Yat-sen University
ACTIVE_NOT_RECRUITING

Guangzhou, Guangdong, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.